Nonpalpable stage T1c prostate cancer: Prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings

Journal of Urology

Volumn 160, Issue 6 II, 1998, Pages 2407-2411

  Epstein, Jonathan I ^a   Chan, Daniel W ^b   Sokoll, Lori J ^b   Walsh, Patrick C ^b   Cox, Jennifer L ^b   Rittenhouse, Harry ^b   Wolfert, Robert ^b   Carter, H Ballentine ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b NONE

Author keywords

Adenocarcinoma; Pathology; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; ARTICLE; CANCER STAGING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SEMINAL VESICLE; TUMOR VOLUME;

EID: 0032823983     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)62200-6     Document Type: Article

References (26)

1. Epstein, J. I., Walsh, P. C., Carmichael, M. and Brendler, C. B.: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. J.A.M.A., 271: 368, 1994.
2. Carter, H. B., Sauvageot, J., Walsh, P. C. and Epstein, J. I.: Prospective evaluation of men with stage T1c adenocarcinoma of the prostate. J. Urol., 157: 2206, 1997.
3. Rahmouni, A., Yang, A., Tempany, C. M., Frenkel, T., Epstein, J., Walsh, P., Leichner, P. K., Ricci, C. and Zerhouni, E.: Accuracy of in-vivo assessment of prostatic volume by MRI and transrectal ultrasonography. J. Comp. Assist. Tomogr., 16: 935, 1992.
4. Matthews, G. J., Motta, J. and Fracehia, K. A.: The accuracy of transrectal ultrasound prostate volume estimation: clinical correlations. J. Clin. Ultrasound, 24: 501, 1996.
5. Bazinet, M., Karakiewicz, P. I., Aprikian, A. G., Trudel, C., Péloquin, F., Dessureault, J., Goyal, M., Begin, L. R. and Elhilali, M. M.: Reassessment of nonplanimetric transrectal ultrasound prostate volume estimates. Urology, 47: 857, 1996.
6. Abrahamsson, P. A., Lilja, H. and Oesterling, J. E.: Molecular forms of serum prostate-specific antigen: the clinical value of percent free prostate-specific antigen. Urol. Clin. N. Amer., 24: 353, 1997.
7. Carter, H. B., Partin, A. W., Luderer, A. A., Metter, E. J., Landis, P., Chan, D. W., Fozard, J. L. and Pearson, J. D.: Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology, 49: 379, 1997.
8. Pannek, J., Rittenhouse, H. G., Chan, D. W., Epstein, J. I., Walsh, P. C. and Partin, A. W.: The use of percent free prostate specific antigen for staging clinically localized prostate cancer. J. Urol., 159: 1238, 1998.
9. Arcangeli, C. G., Shepherd, D. L., Smith, D. S., Humphrey, P. A., Keetch, D. W. and Catalona, W. J.: Correlation of percent free PSA with pathologic features of prostatic carcinomas. J. Urol., part 2, 155: 415A, abstract 420, 1996.
10. Graefen, M., Hammerer, P., Henke, P., Hilz, H., Huland, E. and Huland, J.: Percentage of free PSA does not correlate with pathological outcome. J. Urol., part 2, 155: 370A, abstract 237, 1996.
11. Hendricks, W. H., England, B. G., Giacherio, D. A., Oesterling, J. E. and Wojno, K. J.: Free to total PSA ratio does not predict extraprostatic spread of prostatic adenocarcinoma. J. Urol., part 2, 155: abstract 236, 1996.
12. Epstein, J. I., Carmichael, M., Pizov, G. and Walsh, P. C.: Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. J. Urol., 150: 135, 1993.
13. Elgamal, A. A., Van Poppel, H. P., Van de Voorde, W. M., Van Dorpe, J. A., Oyen, R. H. and Baert, L. V.: Impalpable invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens-a different view. J. Urol., 157: 244, 1997.
14. Douglas, T. H., McLeod, D. G., Mostofi, F. K., Mooneyhan, R., Connelly, R., Moul, J. W. and Sesterhenn, I. A.: Prostate-specific antigen-detected prostate cancer (stage T1c): an analysis of whole-mount prostatectomy specimens. Prostate, 32: 59, 1997.
15. Goto, Y, Ohori, M., Arakawa, A., Kattan, M. W., Wheeler, T. M. and Scardino, P. T.: Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J. Urol., 156: 1059, 1996.
16. Lerner, S. E., Seay, T. M., Blute, M. L., Bergstralh, E. J., Barrett, D. and Zincke, H.: Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis. J. Urol., 155: 821, 1996.
17. Humphrey, P. A., Keetch, D. W., Smith, D. S., Shepherd, D. L. and Catalona, W. J.: Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J. Urol., 155: 816, 1996.
18. Matthews, G. J. and Fracchia, J. A.: PSA-detected prostate cancer: contrasts with palpable disease. J. Surg. Oncol., 59: 28, 1995.
19. Cookson, M. S., Flesher, N. E., Soloway, S. M. and Fair, W. R.: Prognostic significance of prostate-specific antigen in stage T1c prostate cancer treated by radical prostatectomy. Urology, 49: 887, 1997.
20. Scaletscky, R., Koch, M. O., Eckstein, C. W., Bicknell, S. L., Gray, G. F., Jr. and Smith, J. A., Jr.: Tumor volume and stage in carcinoma of the prostate detected by elevations in prostate specific antigen. J. Urol., 152: 129, 1994.
21. Ohori, M., Wheeler, T. M., Greene, D. R. and Scardino, P. T.: Comparison of the pathologic features and DNA ploidy value of prostate cancers detectable by sonography and by palpation. Prostate, 23: 271, 1993.
22. Oesterling, J. E., Suman, V. J., Zincke, H. and Bostwick, D. G.: PSA-detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumors. Urol. Clin. N. Amer., 20: 687, 1993.
23. Stormont, T. J., Farrow, G. M., Myers, R. P., Blute, M. L., Zincke, H., Wilson, T. M. and Oesterling, J. E.: Clinical stage B0 or T1c prostate cancer: nonpalpable disease identified by elevated serum prostate-specific antigen concentration. Urology, 41: 3, 1993.
24. Guthman, D. A., Wilson, T. M., Blute, M. L., Bergstralh, E. J., Zincke, H. and Oesterling, J. E.: Biopsy-proved prostate cancer in 100 consecutive men with benign digital rectal examination and elevated serum prostate-specific antigen level. Prevalence and pathologic characteristics. Urology, 42: 150, 1993.
25. McNeal, N. E., Villers, A. A., Redwine, E. A., Freiha, F. S. and Stamey, T. A.: Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer, 66: 1225, 1990.
26. Epstein, J. I., Walsh, P. C., Sauvageot, J. and Carter, H. B.: Utility of repeat sextant and transition zone biopsies for assessing extent of prostate cancer. J. Urol., 158: 1886, 1997.